Yeshurun M - Search Results

1

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.

Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A. Rubio MT, et al. Among authors: yeshurun m. J Hematol Oncol. 2017 Jan 24;10(1):31. doi: 10.1186/s13045-016-0389-4. J Hematol Oncol. 2017. PMID: 28118857 Free PMC article.

2

Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.

Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Yeshurun M, Daniely M, Zilberstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L. Shimoni A, et al. Among authors: yeshurun m. Leukemia. 2002 Aug;16(8):1413-8; discussion 1419-22. doi: 10.1038/sj.leu.2402581. Leukemia. 2002. PMID: 12145678

3

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.

Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Leukemia. 2003 Feb;17(2):290-7. doi: 10.1038/sj.leu.2402808. Leukemia. 2003. PMID: 12592325 Clinical Trial.

4

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.

Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Exp Hematol. 2003 May;31(5):428-34. doi: 10.1016/s0301-472x(03)00047-x. Exp Hematol. 2003. PMID: 12763142 Free article.

5

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.

Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Br J Haematol. 2003 Aug;122(3):457-64. doi: 10.1046/j.1365-2141.2003.04446.x. Br J Haematol. 2003. PMID: 12877674 Free article.

6

Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.

Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Biol Blood Marrow Transplant. 2004 Jul;10(7):484-93. doi: 10.1016/j.bbmt.2004.03.002. Biol Blood Marrow Transplant. 2004. PMID: 15205669 Free article.

7

A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.

Laporte JP, Yeshurun M, Fouillard L, Labopin M, Cailliot C, Lesage S, Isnard F, Najman A, Gorin NC. Laporte JP, et al. Among authors: yeshurun m. Leukemia. 2004 Oct;18(10):1717-21. doi: 10.1038/sj.leu.2403427. Leukemia. 2004. PMID: 15295607

8

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.

Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Leukemia. 2005 Jan;19(1):7-12. doi: 10.1038/sj.leu.2403591. Leukemia. 2005. PMID: 15526016

9

A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors.

Robin M, Guardiola P, Devergie A, Yeshurun M, Shapiro S, Esperou H, Ribaud P, Rocha V, Gluckman E, Socié G. Robin M, et al. Among authors: yeshurun m. Leukemia. 2005 Sep;19(9):1613-20. doi: 10.1038/sj.leu.2403821. Leukemia. 2005. PMID: 15990868

10

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.

Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Leukemia. 2006 Feb;20(2):322-8. doi: 10.1038/sj.leu.2404037. Leukemia. 2006. PMID: 16307018 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters